Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

Table 3 Principle outcomes of the constant effect analyses*

	Comparator
Treatment	No drug treatment	Rivastigmine		Donepezil		Galantamine
		1–4 mg	6–12 mg	5 mg	10 mg	16 mg
Rivastigmine
1–4 mg	3.0%** $2,880^† $224,222^¶
6–12 mg	5.8% $514 $36,161	3.0% -$2,370 Dominant
Donepezil
5 mg	6.6% $1,032 $36,161	3.7% -$1,849 Dominant	0.8% $522 $158,875
10 mg	9.5% -$811 Dominant	6.7% -$3,692 Dominant	3.9% -$1,321 Dominant	3.1% -$1,843 Dominant
Galantamine
16 mg	10.2% -$1,134 Dominant	7.5% -$4,015 Dominant	4.6% -$1,644 Dominant	3.9% -$2,166 Dominant	0.8% -$323 Dominant
24 mg	10.3% -$1,366 Dominant	7.6% -$4,246 Dominant	4.7% -$1,876 Dominant	4.0% -$2,398 Dominant	0.9% -$555 Dominant	0.1% -$232 Dominant

* for each drug treatment in the rows the comparison is made relative to the approach in the column ** percent reduction in time spent requiring FTC ^† net costs ^¶ incremental cost per QALY gained

ISSN: 1471-2318